MO-201, a candidate therapeutic for drug-resistant Cancer Stem Cells
- Detailed Technology Description
- This invention comprises novel compounds of the Glycosylated Antitumor Ether Lipid (GAEL) class, which selectively target apoptosis-resistant cancer stem cells in ovarian cancer and breast cancer.
- *Abstract
-
The invention provides novel compounds: Glycosylated antitumor ether lipids (GAELs) α- or β-D-gluco-configured 2-amino-2-deoxy (2-NH2-Glc) sugar moiety linked to a glycerolipid aglycone. These compounds kill cancer cells via a non-apoptic mechanism and are highly active against cancer stem cells. The molecules inhibited the formation of tumorspheres from BT-474 cancer stem cell lines, caused the disintegration of preformed tumorspheres and resulted in total loss of cell viability of the cancer stem cells at concentrations of 3 to 20 μM. In contrast, the related antitumor ether lipid gold standard, edelfosine (currently in clinical development) was much less effective in preventing tumorsphere formation and affecting the viability of the cancer stem cells.
- *Inquiry
- Odd Bres,Ph.D.TechnologyManagerPh:+1(204)474.9407Email: odd.bres@umanitoba.ca
- Country/Region
- USA
